	Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer. Oncologist Mahmud S, Dwyer Orr L, Cline M, Mirsalehi A, Lisi M, Ensley L, Brisbin L, Paulson RS. PMID: 42366674 [PubMed - as supplied by publisher]
	Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study. Oncoimmunology Kim CG, Kim J, Kim IH, Jung EH, Im HS, Kang BW, Park JH, Park JH, Jo J, Kim EJ, Beom SH, Rha SY, Kim SH, Park I, Park SH, Lee JL, Shin SJ. PMID: 42366526 [PubMed - indexed for MEDLINE]
	Fibromyxoid Nephrogenic Adenoma Mimicking Renal Cell Carcinoma: A Diagnostic Pitfall in Fine-Needle Aspiration Cytology. Diagn Cytopathol Gedallovich J, Adeniyi A, Sangoi AR, Qian X, Ernst K. PMID: 42366464 [PubMed - as supplied by publisher]
	Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer. Clin Proteomics Das L. PMID: 42366366 [PubMed - as supplied by publisher]
	Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-12: Pathological Restaging and Omission of Second TURBT in T1 NMIBC. Eur Urol Oncol Chang Y. PMID: 42366142 [PubMed - as supplied by publisher]
	Theory-based dyadic co-learning intervention to enhance family resilience in men with prostate cancer and their spouses in Taiwan: protocol for a randomised controlled trial. BMJ Open Chien CH, Chuang CK, Wu CT, Pang ST, Yu KJ, Lin PH, Liu KL. PMID: 42366001 [PubMed - indexed for MEDLINE]
	Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries. Expert Rev Anticancer Ther Kassick M, Pain D, Becht K, Adefres B, George M, Goel A, Ramiah D, Bassa S, Miriyala R, Mahantshetty U, Grover S. PMID: 42365626 [PubMed - as supplied by publisher]
	Associations between body composition and radiotherapy-related side-effects and health-related quality of life in patients with prostate or lung cancer: sub-analysis of the REQUITE trial. Radiother Oncol Vickers AJ, McSweeney DM, Choudhury A, Weaver J, West C, Kerns S, Azria D, Farcy-Jaquet MP, Chang-Claude J, Dunning A, Lambrecht M, Avuzzi B, De Ruysscher D, Seibold P, Sperk E, Talbot C, Vega A, Veldeman L, Bultijnck R, Webb A, Rosenstein B, Rancati T, Gioscio E, Price G, McWilliam A. PMID: 42364819 [PubMed - as supplied by publisher]
	Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes. Urol Oncol Pratama ADM, Shenelo SA, Kamila RAF, Pramudhito D. PMID: 42364308 [PubMed - as supplied by publisher]
	Deep learning classification of significant prostate cancer on MRI: a systematic review and meta-analysis. Abdom Radiol (NY) Chung C, Michalak J, Rubinov Y, Watts K, Kanmaniraja D, Baca A, Hou W, Duong T. PMID: 42364040 [PubMed - as supplied by publisher]
	Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance. Cancer Cytopathol Sayegh Y, McNutt B, Le MK, Liao IC, Yao K, Ng C, Kohsar A, Shou D, Yu M, Jin Y, Vaickus LJ, Liu X, VandenBussche CJ, Harvey SE, Levy JJ. PMID: 42363782 [PubMed - indexed for MEDLINE]
	Long-term trends in the burden of prostate cancer in the United States from 1990 to 2021: A detailed analysis based on the Global Burden of Disease Study 2021. Medicine (Baltimore) Guo G, Zhang L, Zhang W, Lin J, Lin H, Li X, Huang P. PMID: 42363557 [PubMed - indexed for MEDLINE]
	Exploring shared decision-making in prostate cancer screening within primary health care settings in Portugal: a cross-sectional study. BMC Prim Care Oliveira B, Lopes L, de Oliveira Branco S, Oliveira S, Granja A, Gonçalves F, Pinto J, Silva M, Coelho S, Fraga A, Teves F. PMID: 42363103 [PubMed - as supplied by publisher]
	Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management. Urol Clin North Am Hargis P, Baker H, Wiesen B, Kukreja J. PMID: 42362308 [PubMed - indexed for MEDLINE]
	Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care. Urol Clin North Am Jiang T, Zhao CC, Liao JC. PMID: 42362307 [PubMed - indexed for MEDLINE]
	Economic Considerations in the Management of Superficial Bladder Cancer. Urol Clin North Am Gupta VK, Joyce DD, Wymer KM, Sharma V. PMID: 42362306 [PubMed - indexed for MEDLINE]
	Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care. Urol Clin North Am Fu MZ, Sykes J, Pfail J, Packiam VT. PMID: 42362305 [PubMed - indexed for MEDLINE]
	Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease. Urol Clin North Am Zhu S, Washington SL 3rd, Sekar R, Chu CE. PMID: 42362304 [PubMed - indexed for MEDLINE]
	Surveillance Protocols: Balancing Patient Burden and Cancer Control. Urol Clin North Am Steckenrider H, Delgado J, Ritch C. PMID: 42362303 [PubMed - indexed for MEDLINE]
	Management of High-Risk Non-Muscle-Invasive Bladder Cancer. Urol Clin North Am Tallman JE, Goh AC. PMID: 42362302 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 179533

Page 1 of 8977



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy